GGrantIndex
Sort

48,018 grants matching immunotherapy

Project 1: Glutaminolytic GDH1 activation-dependent immunotherapy resistance in LKB1-mutant lung adenocarcinoma

$416,967
Sumin Kang · Emory University · P01 · FY2023 · CA

Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition

$416,950
Sukyung Woo · State University Of New York At Buffalo · R01 · FY2022 · CA

(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment

$416,939
Ethel Cesarman · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · CA

(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment

$416,939
Ethel Cesarman · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · CA

(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment

$416,939
Ethel Cesarman · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA

(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment

$416,939
Ethel Cesarman · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA

(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment

$416,939
Ethel Cesarman · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · CA

Intravesical Chitosan/IL-12 Immunotherapy for Bladder Carcinoma

$416,897
David Zaharoff · University Of Arkansas At Fayetteville · R15 · FY2014 · CA

Multiple Approaches to Abeta Vaccination in Animal Models

$416,848
David Hastings Cribbs · University Of California-Irvine · R01 · FY2006 · AG

A Multi-Epitope Vaccine for NSCLC and Colon Cancer

$416,823
Idm Pharma, Inc. · R21 · FY2005 · CA

Improving CAR-T cell therapy in metastatic breast cancers by reprogramming obesity-aggravated tumor microenvironment via physical activity

$416,818
Dai Fukumura · Massachusetts General Hospital · R21 · FY2025 · CA

Effects of Complement on the Tumor Microenvironment in Lung Cancer

$416,813
Raphael A. Nemenoff · University Of Colorado Denver · R01 · FY2019 · CA

Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma

$416,787
Cassian Yee · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA

Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma

$416,783
Cassian Yee · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA

Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia

$416,766
Xiaotu Ma · St. Jude Children'S Research Hospital · R01 · FY2023 · CA

Cocaine Vaccine for Methadone Maintained Patients

$416,756
Yale University · R01 · FY2003 · DA

SOUTHWEST ONCOLOGY GROUP--SUMMARY

$416,726
Loyola University Chicago · U10 · FY2002 · CA

HER3-PHF8 signaling axis in triple-negative breast cancer progression

$416,723
Bolin Liu · Lsu Health Sciences Center · R01 · FY2023 · CA

Antibodies as Catalysts

$416,700
Scripps Research Institute · R01 · FY2004 · GM

Antibodies as Catalysts

$416,700
Scripps Research Institute · R01 · FY2003 · GM

NOVEL STRATEGIES FOR THE IMMUNOTHERAPY OF COLON CANCER

$416,700
Scripps Research Institute · R01 · FY2003 · CA

Antibodies as Catalysts

$416,700
Scripps Research Institute · R01 · FY2002 · GM

NOVEL STRATEGIES FOR THE IMMUNOTHERAPY OF COLON CANCER

$416,700
Scripps Research Institute · R01 · FY2002 · CA

Pathogenesis of microbial anterior eye diseases

$416,677
Gerald B Pier · Brigham And Women'S Hospital · R01 · FY2015 · EY

Genetic Mechanisms Controlling Kidney Cancer Immune Escape

$416,677
Haydn Kissick · Emory University · R01 · FY2025 · CA